Baxalta clinical trials

Acquired by Takeda, Jan 8, 2019 · source ↗

The registry lists 111 studies whose lead sponsor is Baxalta. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 15, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 111. List all 111 → · All Takeda studies →

• A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)CompletedNCT02932618Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia BActive, not recruitingNCT01687608Phase 1/2

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia AActive, not recruitingNCT04158934

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted after Baxalta became part of Takeda

• A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)CompletedNCT03393975Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• A Study of BAX 888 in Male Adults With Severe Hemophilia ACompletedNCT03370172Phase 1/2

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)CompletedNCT03879135Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia ACompletedNCT02615691Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDPCompletedNCT02955355Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• RIXUBIS Drug Use-Result Survey (Japan)CompletedNCT02937831

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)CompletedNCT02078427

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)CompletedNCT04346108Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted after Baxalta became part of Takeda

• A Study of ADVATE in People With Hemophilia A in IndiaCompletedNCT04985682Phase 4

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted after Baxalta became part of Takeda

• A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult ParticipantsCompletedNCT04578535Phase 1

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted after Baxalta became part of Takeda

• Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD SubjectsCompletedNCT03277313Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT02549170Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)CompletedNCT02764489Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD SubjectsCompletedNCT03116347Phase 4

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)CompletedNCT02593188

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• RIXUBIS PMS India (RIXUBIS PMS)CompletedNCT03565237Phase 4

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life PracticeCompletedNCT03199794

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B SubjectsTerminatedNCT04394286Phase 1/2

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted after Baxalta became part of Takeda

• Efficacy and Safety of SM101 in the Treatment of IgA NephropathyWithdrawnNCT02605525Phase 2

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe HemophiliaCompletedNCT03185897

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• BAX 802 in CHA With InhibitorsTerminatedNCT02895945Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage StudyCompletedNCT02525861Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency DisordersCompletedNCT00157079Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)CompletedNCT00161993Phase 2

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing SurgeryCompletedNCT00157105Phase 2/3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901CompletedNCT00157053Phase 2/3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia ACompletedNCT02610127

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Phase 2/3 Study of IGSC, 20% in PIDDCompletedNCT01218438Phase 2/3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia ACompletedNCT00289536Phase 4

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Aralast alpha1-proteinase Inhibitor Surveillance StudyTerminatedNCT00313144Phase 4

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• BAX 826 Dose-Escalation Safety StudyCompletedNCT02716194Phase 1

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• BAX 855 PK-guided DosingCompletedNCT02585960Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal CancerTerminatedNCT02448810Phase 2

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell DiseaseTerminatedNCT01987908Phase 2

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• GLASSIA Infusion Rate StudyCompletedNCT01651351Phase 4

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• BAX 855 Pediatric StudyCompletedNCT02210091Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A PatientsCompletedNCT00157157Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for InjectionCompletedNCT00952822Phase 1

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Early Prophylaxis Immunologic Challenge (EPIC) StudyTerminatedNCT01376700Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• BAX 855 ContinuationCompletedNCT01945593Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical ProceduresCompletedNCT01913405Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• BAX 326 Pediatric StudyCompletedNCT01488994Phase 2/3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B PatientsCompletedNCT01174446Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• BAX 326 (rFIX) Continuation StudyCompletedNCT01286779Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)CompletedNCT01736475Phase 2/3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Gammagard Liquid and rHuPH20 in PIDCompletedNCT00814320Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda

• Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)CompletedNCT01410227Phase 3

  Sponsor listed in the registry: Baxalta now part of Shire · First submitted before Baxalta became part of Takeda